We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunologic Changes in Renal Cell Carcinoma Patients Receiving Gamma Interferon.
- Authors
Barna, B.P.; Thomassen, M.J.; Sergi, J.; Murthy, S.; Bukowski, R.M.
- Abstract
Immunologic changes were monitored in 5 patients with metastatic renal cell carcinoma participating in a phase II trial of recombinant interferon gamma (rlFNγ). Treatment consisted of a 4-week period of intravenous infusion of either 0.1 mg/m2 given over 4 h on alternate days (3 times/week) or 2 mg/m2 given over 1 h for 5 days every other week. One minor response was seen at the higher dose level and toxicity was minimal (grades III). Absolute leukocyte counts and lymphocyte subpopulations did not change significantly. Both natural killer cytolytic activity and spontaneous monocyte-mediated tumoricidal activity increased. Prostaglandin E2 synthesis of patient leukocytes was abnormally high and pretreatment levels dropped during treatment. Data suggest that rlFNγ may be potentially useful for enhancing immunologic function in renal cell carcinoma. Copyright © 1991 S. Karger AG, Basel
- Publication
Oncology, 1991, Vol 48, Issue 6, p464
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000226982